(74 days)
Not Found
No
The device description and performance studies focus on traditional microbiological methods (visible growth, color changes, biochemical interpretation) and do not mention any AI/ML components or algorithms for interpretation or analysis.
No.
This device is designed to measure the susceptibility of bacteria to antimicrobial agents and determine their biochemical identification, which is a diagnostic function, not a therapeutic one.
Yes
Explanation: The device is described as quantitatively measuring the susceptibility of bacterial pathogens to antimicrobial agents and determining their biochemical identification, which are diagnostic purposes to inform treatment decisions.
No
The device description clearly outlines a physical panel containing antimicrobial agents and biochemical substrates, which is inoculated with test organisms and incubated. This involves physical components and processes, not solely software.
Yes, this device is an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use explicitly states that the panels are used for "quantitatively measuring... the susceptibility of rapidly growing aerobic and facultative anaerobic bacterial pathogens to a battery of antimicrobial agents and determining the biochemical identification of those organisms." This is a classic description of an in vitro diagnostic test used to analyze biological samples (bacterial pathogens) outside of the body to provide information for diagnosis and treatment.
- Device Description: The description details how the device works by using antimicrobial agents and biochemical substrates to interact with the test organisms in the panel. The results (visible growth or color changes) are then interpreted to determine the MIC and identification, which are diagnostic parameters.
- Performance Studies: The performance studies involve testing the device with bacterial strains (CDC challenge strains and clinical isolates) and comparing the results to a reference panel. This type of testing is conducted to demonstrate the accuracy and reliability of an IVD device.
- Predicate Devices: The listed predicate devices are also IVD devices used for antimicrobial susceptibility testing and identification of microorganisms. This further supports the classification of this device as an IVD.
The device performs tests on biological samples (bacterial pathogens) in vitro (outside the body) to provide information relevant to the diagnosis and treatment of infections.
N/A
Intended Use / Indications for Use
PASCO MIC AND MIC/ID PANELS are used for quantitatively measuring (with the exception of the Breakpoint/ID panel which provides qualitative measurement or category results) the susceptibility of rapidly growing aerobic and facultative anaerobic bacterial pathogens to a battery of antimicrobial agents and determining the biochemical identification of those organisms.
This 510(k) notification is for the addition Ofloxacin to Pasco panels at concentrations of 0.5 to 16 mcg/ml for use in determining the susceptibility of S. pneumoniae and non-pneumococcal streptococci.
Product codes
JTN
Device Description
Varying concentrations of antimicrobial agents (usually in two-fold dilutions) are dispensed into the Pasco panels and the panels are then frozen. Panels are thawed prior to use, inoculated with the test organisms, incubated the traditional 16-24 hours and panels are then observed for visible growth or color changes as described in the package insert.
The lowest concentration of each antimicrobial agent with no apparent visible growth of the test organism is recorded as the minimum inhibitory concentration (MIC). Changes in pH and production of specific metabolites from growth in biochemical substrates are interpreted as described in the package insert for conventional tubed media.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Comparative testing of the Pasco test panel to a reference panel was performed at two sites using CDC challenge strains and clinical isolates.
Test results of the 101 S. pneumoniae strains demonstrated acceptable Essential Agreement (EA) of 99.4% with 1 minor error upon initial testing and an EA of 100% and no minor errors on retesting. No major (M) or very major (VM) errors were observed. Category agreement (CA) was 100% with no additional minor errors noted. Test results of the 130 non-pneumococcal streptococci strains demonstrated acceptable Essential Agreement (EA) of 100% on initial testing. No Major (M) or Very Major (VM) errors were observed. Category Agreement (CA) was 100% with 17 random minor errors noted (all of which were within EA).
QC endpoints for the OC organism S. pneumoniae ATCC 49619 from both the reference and Pasco panels throughout testing were within the recommended NCCLS acceptable range.
Reproducibility testing of 12 organisms at each site provided 9 organisms with on-scale endpoints. Overall reproducibility data demonstrated 100% within the acceptable plus or minus 1 dilution.
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Clinical testing, reproducibility testing and QC performance testing were performed.
Clinical testing: S. pneumoniae strains (n=101), non-pneumococcal streptococci strains (n=130).
Key results: Essential Agreement (EA) of 99.4% for S. pneumoniae on initial testing, 100% on retesting. No major (M) or very major (VM) errors for S. pneumoniae. Category Agreement (CA) of 100% for S. pneumoniae. Essential Agreement (EA) of 100% for non-pneumococcal streptococci. No Major (M) or Very Major (VM) errors for non-pneumococcal streptococci. Category Agreement (CA) of 100% for non-pneumococcal streptococci with 17 minor errors.
Reproducibility testing: 12 organisms per site.
Key results: 100% within plus or minus 1 dilution for reproducibility.
QC performance testing: QC organism S. pneumoniae ATCC 49619.
Key results: QC endpoints were within the recommended NCCLS acceptable range.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Essential Agreement (EA), Category agreement (CA), Reproducibility data.
Predicate Device(s)
K982235, K982156, K980955, K974362, K973317, K973695, K972567, K971951, K946126
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 866.1620 Antimicrobial susceptibility test disc.
(a)
Identification. An antimicrobial susceptibility test disc is a device that consists of antimicrobic-impregnated paper discs used to measure by a disc-agar diffusion technique or a disc-broth elution technique the in vitro susceptibility of most clinically important bacterial pathogens to antimicrobial agents. In the disc-agar diffusion technique, bacterial susceptibility is ascertained by directly measuring the magnitude of a zone of bacterial inhibition around the disc on an agar surface. The disc-broth elution technique is associated with an automated rapid susceptibility test system and employs a fluid medium in which susceptibility is ascertained by photometrically measuring changes in bacterial growth resulting when antimicrobial material is eluted from the disc into the fluid medium. Test results are used to determine the antimicrobial agent of choice in the treatment of bacterial diseases.(b)
Classification. Class II (performance standards).
0
SEP ! 3 1999
510(k) SUMMARY (page I of 2)
| DATE: | June 9, 1999 |
|---|---|
| CONTACT PERSON: | Linda K. Dillon |
| Chuck Lakel | |
| TRADE NAME OF DEVICE: | Pasco MIC and MIC/ID Panels |
| COMMON NAME: | Antimicrobial Susceptibility Test |
| CLASSIFICATION NAME: | Class II Antimicrobial Susceptibility Test Microbiology Panel |
| #83 |
SUBSTANTIAL EQUIVALENCE:
In review of previous 510(k) notifications for the Pasco MIC and MIC/ID panels (most recently: K982235, July 30, 1998 RE: Minocycline; K982156, July 29, 1998 RE: Cefdinir; K980955 May 18, 1998 RE: Trovafloxacin: K974362, February 12, 1998 RE: Cefepime; K973317, November 14, 1997 RE: Cefpodoxime; K973695, November 5, 1997 RE: Meropenem; K972567, August 20,1997 RE: Sparfloxacin; K971951, August 15, 1997 RE: Levofloxacin; and K946126, January 17, 1995 RE: Detection of resistant pneumococci), the FDA has determined the Pasco panels to be substantially equivalent to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments.
The term "substantial equivalence" as used in this 510(k) notification is limited to the definition of substantial equivalence as found in the Federal Food, Drug, and Cosmetic Act, as amended and as applied under 21 CFR 807, Subpart E under which a device can be marketed without pre-market approval or reclassification. A determination of substantial equivalency under this notification is not intended to have any bearing whatsoever on the resolution of patent infringement suits or any other patent matters. No statements related to, or in support of substantial equivalence herein shall be construed as an admission against interest under the US Patent Laws or their application by the courts.
DESCRIPTION OF THE DEVICE:
Varying concentrations of antimicrobial agents (usually in two-fold dilutions) are dispensed into the Pasco panels and the panels are then frozen. Panels are thawed prior to use, inoculated with the test organisms, incubated the traditional 16-24 hours and panels are then observed for visible growth or color changes as described in the package insert.
1
The lowest concentration of each antimicrobial agent with no apparent visible growth of the test organism is recorded as the minimum inhibitory concentration (MIC). Changes in pH and production of specific metabolites from growth in biochemical substrates are interpreted as described in the package insert for conventional tubed media.
INTENDED USE FOR THE PASCO MIC AND MIC/ID PANELS:
PASCO MIC AND MIC/ID PANELS are used for quantitatively measuring (with the exception of the Breakpoint/ID panel which provides qualitative measurement or category results) the susceptibility of rapidly growing aerobic and facultative anaerobic bacterial pathogens to a battery of antimicrobial agents and determining the biochemical identification of those organisms.
SUMMARY/CONCLUSION OF SUBSTANTIAL EQUIVALENCE TESTING:
Test panels containing Ofloxacin at concentrations ranging from 16 to 0.5 mcg/ml were prepared in-house at Pasco using routine manufacturing procedures. Comparative testing of the Pasco test panel to a reference panel was performed at two sites using CDC challenge strains and clinical isolates.
Test results of the 101 S. pneumoniae strains demonstrated acceptable Essential Agreement (EA) of 99.4% with 1 minor error upon initial testing and an EA of 100% and no minor errors on retesting. No major (M) or very major (VM) errors were observed. Category agreement (CA) was 100% with no additional minor errors noted. Test results of the 130 non-pneumococcal streptococci strains demonstrated acceptable Essential Agreement (EA) of 100% on initial testing. No Major (M) or Very Major (VM) errors were observed. Category Agreement (CA) was 100% with 17 random minor errors noted (all of which were within EA).
QC endpoints for the OC organism S. pneumoniae ATCC 49619 from both the reference and Pasco panels throughout testing were within the recommended NCCLS acceptable range.
Reproducibility testing of 12 organisms at each site provided 9 organisms with on-scale endpoints. Overall reproducibility data demonstrated 100% within the acceptable plus or minus 1 dilution.
The results of the clinical testing, reproducibility testing and QC performance testing supports Substantial Equivalence as outlined in the FDA draft document "Review Criteria For Assessment Of Antimicrobial Susceptibility Devices" (May 1991).
2
Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is a stylized symbol that resembles a caduceus, a traditional symbol of medicine, but with three wavy lines instead of snakes.
SEP 3 1999
Food and Drug Administration 2098 Gaither Road Rockville MD 20850
Ms. Linda K. Dillon Technical Manager Pasco Laboratories, Inc. 12750 West Forty-Second Avenue Wheat Ridge, Colorado 80033
Re: K992077 Trade Name: PASCO MIC and MIC/ID Panels Regulatory Class: II Product Code: JTN Dated: June 9, 1999 Received: June 21, 1999
Dear Ms. Dillon:
We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.
3
Page 2
Under the Clinical Laboratory Improvement Amendments of 1988 (CLIA-88), this device may require a CLIA complexity categorization. To determine if it does, you should contact the Centers for Disease Control and Prevention (CDC) at (770) 488-7655.
This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification"(21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".
Sincerely yours,
Steven Sutman
Steven I. Gutman, M.D. M.B.A. Director Division of Clinical Laboratory Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
Device Name:
PASCO MIC and MIC/ID Panels; Inclusion of Ofloxacin
Indication For Use:
Pasco MIC and MIC/ID panels are used for quantitatively measuring (with the exception of the Breakpoint/ID panel which provides qualitative measurement of category results) the susceptibility of rapidly growing aerobic and facultative anaerobic bacterial pathogens to a battery of antimicrobial agents and determining the biochemical identification of those organisms.
This 510(k) notification is for the addition Ofloxacin to Pasco panels at concentrations of 0.5 to 16 mcg/ml for use in determining the susceptibility of S. pneumoniae and non-pneumococcal streptococci.
Woody Dubois
vision of Clinical Laboratory Devices K 99 510(k) Number_
PRESCRIPTION USE X